Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medazepam is a long‐acting benzodiazepine derivative used primarily for its anxiolytic, sedative, anticonvulsant, and skeletal muscle relaxant properties. It acts as a prodrug that is metabolized to nordazepam and other active benzodiazepines, contributing to its prolonged therapeutic effect. Medazepam enhances inhibitory neurotransmission in the central nervous system by allosteric modulation of the GABA(A) receptor complex, increasing the effect of gamma‐aminobutyric acid (GABA), the main inhibitory neurotransmitter in the brain. This results in reduced neuronal excitability and produces calming effects useful for treating anxiety disorders. It may also be prescribed for insomnia related to anxiety or stress and has been used off-label for conditions such as muscle spasms or certain gastrointestinal disorders when combined with other agents[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on medazepam.